AVI BioPharma CEO to Present at International Science Symposium On SARS in China.Business Editors/Health/Medical Writers International Science Symposium on SARS PORTLAND, Ore.--(BUSINESS WIRE)--July 9, 2003 AVI BioPharma, Inc. (Nasdaq:AVII) (Nasdaq:AVIIW) (Nasdaq:AVIIZ), today announced that Denis R. Burger, Ph.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of AVI BioPharma, will present an overview of the development of NEUGENE(R) antisense drugs to combat the severe acute respiratory syndrome Severe Acute Respiratory Syndrome (SARS) Definition Severe acute respiratory syndrome (SARS) is the first emergent and highly transmissible viral disease to appear during the twenty-first century. (SARS) virus at the International Science Symposium on SARS, July 10-11, 2003, in Beijing. "I am honored to share our SARS experience at the International Science Symposium, and look forward to forming a strong working relationship with the international delegates around this important public health issue," said Dr. Burger. "Our achievements and expertise in developing third-generation NEUGENE antisense drugs against single-stranded RNA viruses provide valuable insights in the fight against viral outbreaks." The scientific symposium is being co-sponsored by the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health, the Beijing Municipal Government, the Chinese Academy of Sciences The Chinese Academy of Sciences (CAS) (Simplified Chinese: 中国科学院; Pinyin: Zhōngguó Kēxuéyuàn), formerly known as Academia Sinica , the Chinese Academy of Engineering The Chinese Academy of Engineering (Chinese: 中国工程院; Pinyin: Zhōngguó Gōngchéng Yuàn) is the national academy of the People's Republic of China for engineering. and the National Natural Science Foundation of China. The symposium will discuss four main topics on SARS: epidemiology, diagnosis technologies, therapeutic drugs for atypical pneumonia, and research and development into vaccines and clinical treatments. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. and other cell proliferation disorders. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus West Nile virus, microorganism and the infection resulting from it, which typically produces no symptoms or a flulike condition. The virus is a flavivirus and is related to a number of viruses that cause encephalitis. , SARS coronavirus, calicivirus, and Hepatitis C. AVI's second technology, AVICINE(R), is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic and colorectal cancer. More information about AVI is available on the company's Web site at http://www.avibio.com/. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion